Cell storage rate of approximately 3% for the fiscal year ending March 2028
First written in FY2023. 5 of 8 entries say "Advanced", first in FY2024-Q3. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「As part of its overseas expansion, the Company established the Singapore subsidiary STEMCELL INNOVATIONS PTE. LTD. in November 2024 and is preparing to commence operations in the middle of the fiscal year ending March 2027. The cell processing center and cell storage center will be completed in June 2026, bringing the development of the business infrastructure to its final stage.」
For its Singapore operations, the Company set out plans to complete the cell processing and storage centers and commence operations in the middle of the fiscal year ending March 2027, indicating that its overseas expansion had progressed from the preparation stage to the final stage of establishing the business infrastructure. - FY2026-H1AdvancedAnnual report
「The new “HOPECELL” storage plan, introduced in November 2024, collects and stores both cord blood and umbilical cord tissue, enabling more reliable storage of valuable cells available only at childbirth. The plan is steadily gaining market traction. As a result, average revenue per customer increased compared with the previous plan, while the number of new umbilical cord storage contracts rose sharply to approximately 2.1 times the year-earlier level.」
The number of new umbilical cord storage cases was approximately 2.1 times higher year on year following the introduction and penetration of HOPECELL, demonstrating progress toward the medium-term target of a storage rate of approximately 3%, or 20,000 cases. - FY2025RestatedAnnual report
「The current annual domestic storage rate for umbilical cord blood is approximately 1%, compared with approximately 3% in the United States and approximately 20% in Singapore. The Company will first aim to achieve a domestic annual storage rate of 3%, or 20,000 cases.」
The Company reconfirmed its storage target of 3%, or 20,000 cases, based on the current domestic annual storage rate of approximately 1%. - FY2025-H1AdvancedAnnual report
「As a result, the Company set new record highs for the number of specimens stored, comprising umbilical cords and umbilical cord blood, revenue and profit at every stage.」
The Company demonstrated progress toward its medium-term targets of a storage rate of approximately 3% relative to the number of births and 20,000 specimens, with the number of specimens stored, revenue and profit at every stage reaching record highs. - FY2024AdvancedAnnual report
「Offline marketing at medical institutions, principally obstetric facilities, a key marketing channel that had been restricted during the COVID-19 pandemic, recovered substantially. The synergistic effects with digital marketing, including online advertising and social media, resulted in a record number of specimens stored, and the Company is progressing steadily toward its medium-term target of a 3% storage rate relative to the number of births, with expected revenue of approximately ¥6 billion and operating profit of approximately ¥1.8 billion upon achievement.」
The synergistic effects of offline and digital marketing brought the number of specimens stored to a record high, demonstrating progress toward the medium-term targets of a 3% storage rate, approximately ¥6 billion in revenue and approximately ¥1.8 billion in operating profit upon achievement. - FY2024-Q3AdvancedAnnual report
「Offline marketing at medical institutions, principally obstetric facilities, a key marketing channel that had been restricted during the COVID-19 pandemic, recovered substantially. The synergistic effects with digital marketing, including online advertising and social media, resulted in a record number of specimens stored, and the Company is progressing steadily toward its medium-term target of a 3% storage rate relative to the number of births, with expected revenue of approximately ¥6 billion and operating profit of approximately ¥1.8 billion upon achievement.」
The recovery and synergistic effects of offline and digital marketing brought the number of specimens stored to a record high, demonstrating progress toward the 3% storage-rate target for the fiscal year ending March 2028. - FY2024-Q2RestatedAnnual report
「The Company is progressing steadily toward its medium-term target of a 3% storage rate relative to the number of births, with expected revenue of approximately ¥6 billion and operating profit of approximately ¥1.8 billion upon achievement.」
The Company stated StemCell Research Institute's medium-term target of a 3% storage rate relative to the number of births, with expected revenue of approximately ¥6 billion and operating profit of approximately ¥1.8 billion upon achievement, and said that progress remained steady. - FY2023First statedAnnual report
「Through the synergistic effects of digital marketing launched during the COVID-19 pandemic, including web advertising, SEO and online seminars, and conventional offline marketing, including speeches at maternity classes held at obstetric facilities, the Company aims to achieve a medium-term target for the fiscal year ending March 2028 of a cell storage rate of approximately 3% of all births in Japan and an operating margin of 30%.」
The Company identified a cell storage rate of approximately 3% of all births in Japan as a medium-term target for the fiscal year ending March 2028, with combined digital and offline marketing as the means of achieving it. The 30% operating margin target updated the previous operating margin target.